| 創建日期 | 上市日期 | 董事長 | 總經理 |
|---|---|---|---|
| 53/05/19 | 99/12/20 | 王謝怡貞 | 魏慶鵬 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| 0.38(Q2) | 11.9 | 1.43 | 2.12% |
| 實收資本額 | 已發行普通股 | ||
| 775,600,000 | 77,560,000 | ||
| 主要經營業務 | |||
| 原料藥製造銷售 | |||
| 公司網址 | |||
| ccsb.com.tw | |||
中化生(1762) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 158,641 | 156,945 | 49.3% | 1.1% | 1,556,847 | 1,396,595 | 11.5% |
| 2023/07 | 106,273 | 130,715 | -19.6% | -18.7% | 1,398,206 | 1,239,650 | 12.8% |
| 2023/06 | 132,165 | 239,655 | -27% | -44.8% | 1,291,933 | 1,108,935 | 16.5% |
| 2023/05 | 181,028 | 120,712 | -15.1% | 50% | 1,159,768 | 869,280 | 33.4% |
| 2023/04 | 213,290 | 219,036 | -1.7% | -2.6% | 978,740 | 748,568 | 30.7% |
| 2023/03 | 216,908 | 268,869 | -24.1% | -19.3% | 765,450 | 529,532 | 44.5% |
| 2023/02 | 285,652 | 117,001 | 8.6% | 144.1% | 548,542 | 260,663 | 110.4% |
| 2023/01 | 262,890 | 143,662 | 77.5% | 83% | 262,890 | 143,662 | 83% |
| 2022/12 | 148,138 | 241,357 | -15.4% | -38.6% | 2,117,142 | 1,934,702 | 9.4% |
| 2022/11 | 175,154 | 129,732 | -20.1% | 35% | 1,969,004 | 1,693,345 | 16.3% |
| 2022/10 | 219,183 | 136,579 | 23.1% | 60.5% | 1,793,850 | 1,563,613 | 14.7% |
| 2022/09 | 178,072 | 133,463 | 13.5% | 33.4% | 1,574,667 | 1,427,034 | 10.3% |
| 2022/08 | 156,945 | 175,815 | 20.1% | -10.7% | 1,396,595 | 1,293,571 | 8% |
| 2022/07 | 130,715 | 196,314 | -45.5% | -33.4% | 1,239,650 | 1,117,756 | 10.9% |
| 2022/06 | 239,655 | 230,689 | 98.5% | 3.9% | 1,108,935 | 921,442 | 20.3% |
| 2022/05 | 120,712 | 189,610 | -44.9% | -36.3% | 869,280 | 690,753 | 25.8% |
| 2022/04 | 219,036 | 79,533 | -18.5% | 175.4% | 748,568 | 501,143 | 49.4% |
| 2022/03 | 268,869 | 136,367 | 129.8% | 97.2% | 529,532 | 421,610 | 25.6% |
| 2022/02 | 117,001 | 119,871 | -18.5% | -2.4% | 260,663 | 285,243 | -8.6% |
| 2022/01 | 143,662 | 165,372 | -40.5% | -13.1% | 143,662 | 165,372 | -13.1% |
| 2021/12 | 241,357 | 146,960 | 86% | 64.2% | 1,934,702 | 1,543,590 | 25.3% |
| 2021/11 | 129,732 | 171,870 | -5% | -24.5% | 1,693,345 | 1,396,630 | 21.2% |
| 2021/10 | 136,579 | 240,784 | 2.3% | -43.3% | 1,563,613 | 1,224,760 | 27.7% |
| 2021/09 | 133,463 | 62,016 | -24.1% | 115.2% | 1,427,034 | 983,976 | 45% |
| 2021/08 | 175,815 | 98,590 | -10.4% | 78.3% | 1,293,571 | 921,960 | 40.3% |
| 2021/07 | 196,314 | 124,018 | -14.9% | 58.3% | 1,117,756 | 823,370 | 35.8% |
| 2021/06 | 230,689 | 121,894 | 21.7% | 89.3% | 921,442 | 699,352 | 31.8% |
| 2021/05 | 189,610 | 85,882 | 138.4% | 120.8% | 690,753 | 577,458 | 19.6% |
| 2021/04 | 79,533 | 184,136 | -41.7% | -56.8% | 501,143 | 491,576 | 1.9% |
| 2021/03 | 136,367 | 113,883 | 13.8% | 19.7% | 421,610 | 307,440 | 37.1% |
| 2021/02 | 119,871 | 57,109 | -27.5% | 109.9% | 285,243 | 193,557 | 47.4% |
| 2021/01 | 165,372 | 136,448 | 12.5% | 21.2% | 165,372 | 136,448 | 21.2% |
| 2020/12 | 146,960 | 105,740 | -14.5% | 39% | 1,543,590 | 1,156,640 | 33.5% |
| 2020/11 | 171,870 | 87,831 | -28.6% | 95.7% | 1,396,630 | 1,050,900 | 32.9% |
| 2020/10 | 240,784 | 82,561 | 288.3% | 191.6% | 1,224,760 | 963,069 | 27.2% |
| 2020/09 | 62,016 | 111,450 | -37.1% | -44.3% | 983,976 | 880,508 | 11.8% |
中化生(1762) 歷年營收季增率
| 年度/季別 | 營收季增率 | 近4季營收季增率 | 年度/季別 | 營收季增率 | 近4季營收季增率 |
|---|---|---|---|---|---|
| 2023Q2 | -31.22% | -2.25% | 2020Q3 | -27.38% | 5.67% |
| 2023Q1 | 41.10% | 11.14% | 2020Q2 | 27.48% | 6.61% |
| 2022Q4 | 16.48% | 1.67% | 2020Q1 | 11.34% | -3.29% |
| 2022Q3 | -19.62% | -1.88% | 2019Q4 | 27.24% | 4.10% |
| 2022Q2 | 9.42% | 3.90% | 2019Q3 | -31.76% | 3.46% |
| 2022Q1 | 4.31% | 5.58% | 2019Q2 | -7.94% | -1.38% |
| 2021Q4 | 0.41% | -2.61% | 2019Q1 | 49.85% | 6.82% |
| 2021Q3 | 1.15% | 12.51% | 2018Q4 | 28.17% | -9.98% |
| 2021Q2 | 18.55% | 6.51% | 2018Q3 | -46.00% | -13.84% |
| 2021Q1 | -24.66% | 7.40% | 2018Q2 | 20.70% | 12.15% |
| 2020Q4 | 96.62% | 22.50% | 2018Q1 | -19.67% | 0.32% |
評論0